1.
13例接受尼妥珠单抗联合化疗治疗的晚期肺鳞癌患者的临床资料
The characteristics of the 13 patients with advanced squamous cell lung cancer who treated with nimotuzumab combined with chemotherapy
| No. | Gender | Age (yr) | Stage | Treatment lines | EGFR IHC | Combined CT regimens | Cycles | Response | PFS (mo) |
| EGFR: epidermal growth factor receptor; IHC: immunohistochemistry; mo: months; NA: not available; PTX: paclitaxel; CBP: carboplatin; DDP: cisplatin; CPT-11: irinotecan; NDP: nedaplatin; TXT: docetaxel; GEM: gemcitabine; CT: chemotherapy; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; a: change to receive radiotherapy. | |||||||||
| 1 | Male | 48 | Ⅳ | 2nd | NA | PTX+CBP | 2 | PD | 2.4 |
| 2 | Female | 55 | Ⅳ | 3rd | 3+ | PTX+DDP | 6 | PR | 6.7 |
| 3 | Male | 58 | Ⅳ | 3rd | NA | CPT-11+NDP | 2 | PD | 1.6 |
| 4 | Female | 46 | Ⅳ | 3rd | NA | S1+NDP | 4 | PD | 3.1 |
| 5 | Female | 49 | Ⅳ | 3rd | NA | Nab-PTX | 4 | PR | 2.9 |
| 6 | Male | 62 | Ⅳ | 2nd | 2+ | PTX+CBP | 4 | SD | 3.9 |
| 7 | Male | 64 | Ⅳ | 2nd | 3+ | PTX+CBP | 4 | CR | 22.2 |
| 8 | Male | 62 | Ⅳ | 2nd | NA | Nab-PTX | 2 | PD | 1.5 |
| 9 | Male | 64 | Ⅲb | 3rd | 3+ | PTX+CBP | 3 | SD | 1.6a |
| 10 | Male | 59 | Ⅲb | 2nd | 3+ | TXT+NDP | 4 | SD | 2.2a |
| 11 | Male | 60 | Ⅳ | 2nd | NA | TXT+DDP | 2 | PD | 1.5 |
| 12 | Male | 55 | Ⅲb | 2nd | 3+ | TXT+DDP | 3 | SD | 2.5a |
| 13 | Male | 72 | Ⅳ | 3rd | NA | GEM | 2 | PD | 1.8 |